Beam Therapeutics Inc.
BEAM | NASDAQ
$25.26
+$0.31 (+1.24%)
At close: Sep 21, 2026, 4:00 PM ET
$25.35
+$0.09 (+0.36%)
Pre-market:
Sep 22, 2026, 6:20 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 139.74M | 63.52M | 377.71M | 60.92M | 51.84M | 24K |
Cost of Revenue | 22.29M | 367.56M | n/a | 311.59M | 232.13M | 103.18M |
Gross Profit | 117.45M | -304.04M | 377.71M | -250.67M | -180.29M | -103.16M |
Operating Income | -383.69M | -415.57M | -176.49M | -338.48M | -392.47M | -132.76M |
Interest Income | n/a | 49.09M | 46.68M | 15.3M | n/a | 1.57M |
Pretax Income | -79.99M | -376.7M | -131.16M | -285.68M | -370.64M | -194.59M |
Net Income | -79.99M | -376.74M | -132.53M | -289.09M | -370.64M | -194.59M |
Selling & General & Admin | 113.82M | 111.53M | 116.81M | 87.81M | 57.22M | 29.61M |
Research & Development | 409.62M | 367.56M | 437.38M | 311.59M | 387.09M | 103.18M |
Other Expenses | -22.29M | -367.56M | n/a | -311.59M | -232.13M | -103.18M |
Operating Expenses | 501.14M | 111.53M | 554.19M | 87.81M | 212.18M | 29.6M |
Interest Expense | 43.73M | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 523.44M | 479.09M | 554.19M | 399.4M | 444.31M | 132.78M |
Income Tax Expense | n/a | 39K | 1.37M | 3.41M | n/a | n/a |
Shares Outstanding (Basic) | 98.91M | 82.31M | 77.15M | 70.02M | 64.23M | 46.73M |
Shares Outstanding (Diluted) | 98.91M | 82.31M | 77.15M | 70.02M | 64.23M | 46.73M |
EPS (Basic) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -5.49 |
EPS (Diluted) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -5.49 |
EBITDA | -29.92M | -354.78M | -101.63M | -271.53M | -230.06M | -128.03M |
EBIT | -36.26M | -376.7M | -131.16M | -285.68M | -237.51M | -132.76M |
Depreciation & Amortization | 6.34M | 21.93M | 29.53M | 14.15M | 7.45M | 4.73M |
Add to Watchlist
Select watchlists to add or remove BEAM